BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Sanofi SA

Затворен

СекторЗдравеопазване

92.54 -0.88

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

92.18

Максимум

94.26

Ключови измерители

By Trading Economics

Приходи

-2.3B

499M

Продажби

-6.5B

7.6B

P/E

Средно за сектора

20.663

57.333

EPS

1.31

Дивидентна доходност

4.32

Марж на печалбата

6.539

Служители

82,878

EBITDA

-3.7B

563M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+22.28% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.32%

2.63%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-20B

111B

Предишно отваряне

93.42

Предишно затваряне

92.54

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

Sanofi SA Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 08:52 ч. UTC

Печалби

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24.04.2025 г., 05:44 ч. UTC

Печалби

Sanofi Sales, Profit Beat Expectations

9.04.2025 г., 06:00 ч. UTC

Придобивния, сливания и поглъщания

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20.03.2025 г., 06:43 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24.04.2025 г., 12:54 ч. UTC

Пазарно говорене
Печалби

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24.04.2025 г., 10:06 ч. UTC

Пазарно говорене
Печалби

Sanofi Starts the Year Strong -- Market Talk

10.04.2025 г., 12:06 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10.04.2025 г., 09:10 ч. UTC

Горещи акции

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9.04.2025 г., 10:49 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9.04.2025 г., 08:19 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9.04.2025 г., 06:59 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9.04.2025 г., 06:46 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4.04.2025 г., 09:07 ч. UTC

Горещи акции

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3.04.2025 г., 07:51 ч. UTC

Пазарно говорене

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2.04.2025 г., 13:44 ч. UTC

Пазарно говорене

Santander Push Into Canada on the Cards -- Market Talk

2.04.2025 г., 09:27 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26.03.2025 г., 06:19 ч. UTC

Пазарно говорене
Печалби

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25.03.2025 г., 10:08 ч. UTC

Пазарно говорене

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20.03.2025 г., 09:00 ч. UTC

Топ новини

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20.03.2025 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20.03.2025 г., 06:05 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20.03.2025 г., 06:04 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Pay $600M Upfront

20.03.2025 г., 06:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20.03.2025 г., 06:00 ч. UTC

Придобивния, сливания и поглъщания

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18.03.2025 г., 09:33 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17.03.2025 г., 23:00 ч. UTC

Топ новини

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13.03.2025 г., 09:50 ч. UTC

Печалби

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13.03.2025 г., 09:49 ч. UTC

Печалби

Santander Increased 2024 Cash Payments by 19%

24.02.2025 г., 08:56 ч. UTC

Пазарно говорене
Печалби

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24.02.2025 г., 08:30 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Sanofi SA Прогноза

Ценова цел

By TipRanks

22.28% нагоре

12-месечна прогноза

Среден 114.144 EUR  22.28%

Висок 127 EUR

Нисък 83.729 EUR

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Sanofi SA през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

14 ratings

10

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

91.62 / 93.4Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Strong Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.